Literature DB >> 20735210

Antitumor activity of theophylline in combination with Paclitaxel: a preclinical study on melanoma experimental lung metastasis.

Alessandro Lentini1, Claudio Tabolacci, Palma Mattioli, Bruno Provenzano, Simone Beninati.   

Abstract

Melanoma is one of the most aggressive forms of tumor, being responsible for about 80% of skin cancer deaths. Much effort is being directed at obtaining less-toxic anticancer therapies, and the combination between low cytotoxic doses of chemotherapeutic drugs and natural differentiative compounds seems to be of particular importance. The present study was undertaken to examine the possible role of a combination therapy using paclitaxel (PTX) as chemotherapeutic molecule and theophylline (TH) as differentiative agent in the prevention of metastasis in B16-F10 melanoma-bearing C57BL6/N mice. In vitro proliferation studies demonstrated that TH enhanced the antiproliferative effect of PTX. In the in vivo experiments, a highly sensitive computerized image analysis method, performed on histological lung sections of mice injected with melanoma cells, was used to quantify the efficacy of the treatments. This study demonstrated that the simultaneous treatment of mice with TH and a low dose of PTX produced a similar anti-invasive effect than that caused by highly toxic PTX concentration.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20735210     DOI: 10.1089/cbr.2010.0787

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  3 in total

1.  A novel strain of Aureobasidium sp. TeO12 for theophylline production from caffeine.

Authors:  Morahem Ashengroph
Journal:  3 Biotech       Date:  2017-06-29       Impact factor: 2.406

2.  Identification of a pharmacologically tractable Fra-1/ADORA2B axis promoting breast cancer metastasis.

Authors:  Christophe J Desmet; Tristan Gallenne; Alexandre Prieur; Fabien Reyal; Nils L Visser; Ben S Wittner; Marjon A Smit; Thomas R Geiger; Jamila Laoukili; Sedef Iskit; Boris Rodenko; Wilbert Zwart; Bastiaan Evers; Hugo Horlings; Abderrahrim Ajouaou; John Zevenhoven; Martin van Vliet; Sridhar Ramaswamy; Lodewyk F A Wessels; Daniel S Peeper
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-12       Impact factor: 11.205

3.  Potential synergistic effect of phosphodiesterase inhibitors with chemotherapy in lung cancer.

Authors:  Kalliopi Domvri; Konstantinos Zarogoulidis; Nikolaos Zogas; Paul Zarogoulidis; Savvas Petanidis; Konstantinos Porpodis; Efrosini Kioseoglou; Wolfgang Hohenforst-Schmidt
Journal:  J Cancer       Date:  2017-10-09       Impact factor: 4.207

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.